Bexacat is a drug owned by ELANCO US INC. It is protected by 6 US drug patents filed from 2028 to 2032. All patents are active. Details of Bexacat’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US10981942 | 13 Jun, 2031 | Active |
| US7838499 | 30 Jan, 2029 | Active |
| US8802637 | 22 Aug, 2028 | Active |
| US8106021 | 22 Aug, 2028 | Active |
Exclusivity Information
Bexacat holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Bexacat's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Dec 08, 2027 |
About Bexacat
Bexacat is a drug
owned by ELANCO US INC.
Bexacat uses
Bexagliflozin as the active
ingredient.
Active Ingredient:
Bexacat uses
Bexagliflozin as the active ingredient.
Check out other Drugs and Companies using
Bexagliflozin ingredient.